Nov. 13 at 5:59 PM
$CGTX it is interesting they are putting effort into START and stopped on MAGNIFY. I thought the preliminary data on MAGNIFY was positive, and that is a sizable population target. I also wonder if it would have made more sense to focus resources and effort onto the phase 3 trials, and from there dangle another fast track for START, assuming those numbers were positive since it would reflect early disease onset? I do need to do some more research into it, but curious on thoughts about it.
The 18-month timeline for START is also another reminder how much of a big deal the fast track for phase 3 is (whenever that gets kicked off).
